UHS Surpasses Q2 Goals, Boosts 2025 Outlook with Medicaid Growth and Expansion

Strong Financial Performance and Strategic Growth

Universal Health Services, Inc. (UHS) has delivered impressive financial results for the second quarter of 2025, showcasing robust growth in both net income and revenue. The company attributed its success to favorable Medicaid reimbursements and continued expansion in its acute and behavioral health services. In addition, UHS has raised its full-year earnings outlook based on strong performance during the first half of the year.

For the quarter, UHS reported net income attributable to shareholders of $353.2 million, or $5.43 per diluted share. This represents a significant increase from $289.2 million, or $4.26 per share, in the same period of 2024. Quarterly revenue also saw a notable rise, climbing 9.6% year-over-year to $4.28 billion. Adjusted net income, which excludes certain one-time items, reached $347.9 million, or $5.35 per share, compared to $292.6 million, or $4.31 per share, in the second quarter of the previous year.

The company's earnings were positively impacted by $101 million in net pre-tax supplemental Medicaid reimbursements. These included $58 million related to Tennessee’s newly approved directed payment program and $43 million from other state programs. Notably, these contributions were not factored into UHS’s original 2025 forecast. However, the quarter also included a $25 million pre-tax loss associated with the opening of a new 142-bed acute care hospital in Washington, D.C., which began operations in April. Despite the initial costs, UHS views this as a strategic long-term investment.

Segment Performance Highlights

In the acute care services segment, same-facility adjusted admissions increased by 2.0%, while adjusted patient days rose by 1.1%. Revenue per adjusted admission and patient day grew by 3.8% and 4.7%, respectively, leading to a 7.9% revenue increase for the segment.

Behavioral health services experienced more modest volume gains, with adjusted admissions up 0.4% and adjusted patient days increasing by 1.2%. However, higher pricing drove an 8.9% increase in revenue, fueled by an 8.6% rise in revenue per adjusted admission.

Strong First-Half Results and Cash Flow

For the first six months of 2025, UHS recorded net income attributable to shareholders of $669.9 million, or $10.23 per share, compared to $551.0 million, or $8.08 per share, in the same period of 2024. Revenue for the first half of the year rose 8.2% to $8.38 billion. Adjusted EBITDA net of noncontrolling interests reached $1.24 billion in the first half, up from $1.10 billion in 2024.

Despite the strong earnings, net cash provided by operating activities declined to $909 million in the first half, down from $1.08 billion in the same period last year. This decrease was partly due to unfavorable changes in receivables and tax accruals.

Stock Repurchases and Liquidity

UHS continued its share repurchase program, buying back 1.875 million shares for $331.5 million in the first half of the year. As of June 30, the company had $492.9 million remaining in its repurchase authorization and $1.08 billion in available borrowing capacity.

Revised Full-Year Forecast

Based on favorable reimbursement trends and strong operating momentum, UHS has revised its 2025 financial guidance. The company now expects:

• Net revenue between $17.10 billion and $17.31 billion
• Adjusted EBITDA net of NCI between $2.46 billion and $2.54 billion (up 2.4%–4.3%)
• Adjusted EPS (diluted) between $20.00 and $21.00 (up 5.3%–8.4%)

These projections exclude non-operational items such as investment gains/losses, tax impacts, and potential future acquisitions.

With solid second-quarter earnings and an optimistic outlook for the remainder of the year, UHS appears well-positioned to maintain momentum across both its acute and behavioral health portfolios. The company is supported by ongoing investments and favorable policy shifts in Medicaid funding.